Barriers to CAR T-cell therapy in rheumatology
Lancet Rheumatol 2024 doi: 10.1016/S2665-9913(24)00240-6
Lungova et al. explored the potential of CAR T-cell therapy in autoimmune conditions such as SLE, myopathies, and systemic sclerosis. While clinical cases show promise, adoption is limited by high costs, narrow patient eligibility, and safety concerns, including cytokine release syndrome. Future targeted CAR T-cell approaches may enhance efficacy and safety.
CAR T-cell therapy's current reliance on B-cell depletion presents limited benefits for some autoimmune diseases. The study aimed to address the trajectory differences between rheumatic diseases and malignancies, proposing ways to overcome barriers and enhance its feasibility in rheumatology.